Novartis strong Q3 from key growth drivers, Entresto sales +47%, Zolgensma up 82%

• Novartis (NVS) Q3 results:
• Revenues: $12,259M (+0.7%); Innovative Medicines: $9,837M (+1.5%); Sandoz: $2,422M (-2.5%).
• Top sellers: Cosentyx: $1,012M (+8%); Gilenya: $733M (-12%); Entresto: $632M (+47%); Tasigna: $478M (-2%); Lucentis: $515M (+3%); Promacta/Revolade: $442M (+16%); Tafinlar + Mekinist: $397M (+15%); Sandostatin: $361M (-7%); Sandostatin: $361M (-7%); Jakavi: $335M (+20%); Gleevec/Glivec: $280M (-13%); Xolair: $320M (+7%); Afinitor/Votubia: $262M (-35%); Ilaris: $220M (+24%); Exjade/Jadenu: $162M (-36%); Zolgensma: $291M (+82%); Kisqali: $183M (+49%); Votrient: $160M (-19%).
• Net Income: $1,932M (-5.3%); EPS: $0.85 (-5.6%); non-GAAP Net Income: $3,467M (+7.9%); non-GAAP EPS: $1.52 (+7.8%).
• CF Ops: $3,156M (-30.8%).
• 2020 guidance: Net sales growth: mid single digit; Innovative Medicines: grow mid single digit (unch); Sandoz:  expected to grow broadly in line with prior year, decreased from low-single digit growth; Core operating income: upgraded to low double digit to mid teens from low double digit.
• Key innovation milestones: Kesimpta approved and launched in the U.S. for treatment of relapsing forms of multiple sclerosis.
• Piqray received EC approval for HR+/HER2- advanced breast cancer.
• Leqvio (Inclisiran) and Adakveo received positive CHMP opinion for hypercholesterolemia/mixed dyslipidemia (Oct) and for prevention of vaso-occlusive crises in sickle cell disease, respectively.
• https://seekingalpha.com/news/3626180-novartis-delivers-strong-q3-performance-from-key-growth-drivers-entresto-salesplus-47